Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,016.60 | 5.30 | -0.07% |
CAC 40 | 7,285.86 | 44.11 | -0.60% |
DAX 40 | 21,205.86 | 105.16 | -0.49% |
Dow JONES (US) | 38,170.41 | 971.82 | -2.48% |
FTSE 100 | 8,275.66 | 0.06 | 0.00% |
HKSE | 21,305.01 | 90.13 | -0.42% |
NASDAQ | 15,870.90 | 415.55 | -2.55% |
Nikkei 225 | 34,255.71 | 24.21 | -0.07% |
NZX 50 Index | 11,993.23 | 125.76 | -1.04% |
S&P 500 | 5,158.20 | 124.50 | -2.36% |
S&P/ASX 200 | 7,819.20 | 0.10 | 0.00% |
SSE Composite Index | 3,301.67 | 10.24 | 0.31% |